S

Sanofi

Global pharma company; vaccines and R&D

Immunology Franchise Lead

Full-TimeUpdated on 10/23/2026Deadline 12/16/26
$178.5k - $257.8k
Expert
PhD, MD
Swiftwater, PA, USA+2 moreMore locations: Washington, DC, USA | Waltham, MA, USA
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A proven track record leading clinical immunology and/or translational medicine strategy for multiple vaccines, biologics development, or antimicrobial products, including extensive experience with regulatory submissions and health authority interactions.
  • Expertise in designing and executing Phase 1 through Phase 4 global clinical development of preventive and therapeutic infectious disease candidates.
  • Demonstrated leadership skills in a Clinical Development or Translational Medicine setting, preferably in vaccinology, immunology, or infectious diseases.
  • Ability to translate scientific insights into actionable franchise strategy.
  • Experience managing cross-functional teams.
  • Ability to present complex immunology data to regulators, senior leadership, and scientific communities.
  • A strong publications record demonstrating scientific leadership.
  • Deep expertise in immunogenicity assessment, virology, bacteriology, and assay development, with knowledge of Good Clinical Laboratory Practice and International Council for Harmonisation guidelines.
  • Ability to build partnerships across functions and geographies.
  • A PhD in Immunology, Virology, Bacteriology, Microbiology, or a related scientific field, with 10 or more years of relevant industry experience or a combination of industry and academic experience; or an MD in one of those fields, with 5 or more years of relevant industry experience or a combination of industry and academic experience.
  • Three or more years of direct people-leadership experience.
  • Fluent English is required.
Responsibilities
  • Lead the immunology strategy across the vaccine franchise, overseeing the design and execution of immunogenicity, virology, and bacteriology endpoints aligned with franchise objectives and product development goals.
  • Serve as the primary immunology interface with Clinical Franchise Leadership and One Research segment heads, providing scientific and clinical guidance throughout product development and lifecycle management.
  • Establish and manage strategic partnerships with external experts, academic institutes, and key opinion leaders to advance immunology science and strengthen the franchise’s competitive position.
  • Lead and mentor Senior Clinical Immunology Leads and Immunology Leads, fostering their development and ensuring consistent, high-quality immunology deliverables across the franchise.
  • Generate data-driven insights that contextualize vaccine candidates within the franchise, supporting portfolio prioritization and strategic decision-making at key development milestones.
  • Oversee immunology methodologies used to assess vaccine candidates, ensuring they use cutting-edge technologies, meet regulatory standards, and enable robust data generation for clinical trials and regulatory submissions.
Desired Qualifications
  • French language proficiency.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...